Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Controlled, Open-label (Dose-blinded), Multi-center, Dose-finding Study of the Safety and Efficacy of I-0401 in the Treatment of Patients With Fractures of the Tibial Plateau Requiring Grafting.

NCT00409799 is registered in ClinicalTrials.gov with Kuros Biosurgery AG as lead sponsor.

NCT NCT00409799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00409799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Controlled, Open-label (Dose-blinded), Multi-center, Dose-finding Study of the Safety and Efficacy of I-0401 in the Treatment of Patients With Fractures of the Tibial Plateau Requiring Grafting.
Lead sponsor
Kuros Biosurgery AG
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
September 30, 2011
Enrollment
208 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

tibia plateau fractures